Stock Price, News, Quote and Profile of NLS PHARMACEUTICS LTD(NASDAQ:NLSP) stock

NLS PHARMACEUTICS LTD

NASDAQ:NLSP (12/20/2024, 8:00:01 PM)

After market: 1.9 -0.05 (-2.56%)

1.95

-0.43 (-18.07%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

GICS SubIndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%75.66%

Sales Q2Q%N/A

CRS1

6 Month-74.07%

Overview

Earnings (Last)N/A N/A

Earnings (Next)12-13 2022-12-13/bmo

Ins Owners11.45%

Inst Owners25.87%

Market Cap3.86M

Shares1.98M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts43.33

Short Float %7.26%

Short Ratio0.2

IPO01-29 2021-01-29

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

NLS Pharmaceutics AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Zurich, Zuerich and currently employs 3 full-time employees. The company went IPO on 2021-01-29. NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.

Company Info

NLS PHARMACEUTICS LTD

The Circle 6

Zurich ZUERICH CH-6370

P: 41445122150

CEO: Alexander Zwyer

Employees: 7

Website: https://nlspharma.com/

NLSP News

3 days ago - ACCESSWIRENLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

11 days ago - ACCESSWIRENLS Pharmaceutics CEO Issues Letter to Shareholders

18 days ago - NLS Pharmaceutics Ltd.NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

/PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

19 days ago - ChartmillWondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

19 days ago - ACCESSWIRENLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

a month ago - ACCESSWIRENLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

NLS PHARMACEUTICS LTD (NLSP)

Nasdaq Stock Screener

USA Stock Screener